Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
PMID: 20649426
2010
The Journal of infectious diseases
Abstract: V75I and other mutations in HIV-1 reve
Discussion: However, the V75I mutation has a significant fitness cost, and it is possible that any selective advantage conferred by acyclovir resistance did not outweigh the fitness cost at the lower dose of acyclovir used in this study.
Discussion: Our finding contrasts with those of in vitro studies which used very high doses of acyclovir in HIV infectivity models with activated CD4 T cells or tonsillar lymphoid explants and found V75I and other mutations in HIV-1 reverse transcriptase that may confer resistance to some nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection.
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.
Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
PMID: 19358668
2009
The Journal of infectious diseases
Result: Surprisingly, the dose-response profile of Q151M HIV-2ROD was comparable to that of the highly resistant Q151M/A62V/V75I/F77L/F116Y (Q151M+4) HIV-1NL4-3 mutant (figure A2 in appendix A, which appears only in the electronic version of the Journal).
Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
PMID: 19509419
2009
The Journal of biological chemistry
Abstract: V75I compromises binding of the next nucleotide that can otherwise provide a certain degree of protection from excision.
Abstract: Pre-steady-state kinetics reveal that V75I discriminates against the inhibitor at the level of catalysis, whereas binding of the inhibitor remains largely unaffected.
Abstract: The V75I mutation in HIV-1 RT appears to be dominant in this regard.
Abstract: We demonstrate that V75I is also selected under the selective pressure of a monophosphorylated prodrug that was designed to bypass the bottleneck in drug activation to the triphosphate form (ACV-TP).
Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.
Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.
PMID: 19644383
2009
Journal of acquired immune deficiency syndromes (1999)
Result: Among the 13 patients on non-TDF ART, the following NRTI mutations were observed in association with the K65R mutation: Q151M, F77L, F116Y, V75I, M184V, K219R, T69del and S68G.
Increased thermostability and fidelity of DNA synthesis of wild-type and mutant HIV-1 group O reverse transcriptases.
Abstract: V75I caused a loss of efficiency of reverse transcription PCR amplifications at 65 and 68 degrees C in comparison with O_WT RT.
Abstract: However, a double mutant devoid of RNase H activity (V75I/E478Q) was found to reverse-transcribe at temperatures as high as 68 degrees C, while maintaining the increased accuracy of the V75I mutant.
Abstract: In HIV-1 group O RT, substituting Ile75 for Val rendered an enzyme that was 1.9 and 4.7 times more faithful than O_WT RT and BH10_WT RTs, respectively, in forward mutation assays.
Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
PMID: 19801659
2009
The Journal of biological chemistry
Abstract: M41L/A62V/T69SSS/K70R/T215Y), the introduction of V75I led to a significant decrease of its ATP-dependent excision activity on AZT-, d4T-, and acyclovir-terminated primers.
Abstract: In contrast, V75I decreased the PP(i)-mediated unblocking efficiency on AZT and d4T-terminated primers, in different sequence contexts.
Abstract: Recombinant HIV-1 containing the M41L/A62V/T69SSS/K70R/V75I/T215Y RT showed 18.3- and 1.5-fold increased susceptibility to AZT and d4T, respectively, in compari
The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.
Introduction: In addition, AZT and d4T may also select for the more rarely observed Q151M nucleoside analog mutational (NAM) pathway (Q151M, A62V, V75I, F77L and F116Y), which confers broad-spectra NRTI resistance.
Introduction: The development of K65R and Q151M may be facilitated for HIV-2 variants originating from West Africa (Senegal and Portugal), harboring NNRTI mutations (K101A, V106I, V179I, Y181I, Y188L and G190A) and TAM
Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis.
Abstract: Primer extension experiments carried out in the absence of one deoxyribonucleoside-triphosphate suggested that mutations did not affect the accuracy of the RT, except for V75A, V75F, V75I, and to a lesser extent V75T.
Abstract: Specific DNA polymerase activities of mutant RTs bearing amino acid substitutions at position 75 (i.e., V75A, V75F, V75I, V75L, V75M, V75S and V75T) were relatively high.
Abstract: Steady- and pre-steady-state kinetics demonstrated that the increased fidelity of
HIV mutation literature information.
PMID: 
2010
The Journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT